ATE496893T1 - Isochinolinonderivate und deren verwendung als medikamente - Google Patents

Isochinolinonderivate und deren verwendung als medikamente

Info

Publication number
ATE496893T1
ATE496893T1 AT03814127T AT03814127T ATE496893T1 AT E496893 T1 ATE496893 T1 AT E496893T1 AT 03814127 T AT03814127 T AT 03814127T AT 03814127 T AT03814127 T AT 03814127T AT E496893 T1 ATE496893 T1 AT E496893T1
Authority
AT
Austria
Prior art keywords
sup
medications
isoquinolinone derivatives
compounds
disclosed
Prior art date
Application number
AT03814127T
Other languages
English (en)
Inventor
Alan Johnson
Satoru Kaneko
Raju Mohan
Kozo Oda
Edwin Schweiger
Original Assignee
X Ceptor Therapeutics Inc
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Ceptor Therapeutics Inc, Sankyo Co filed Critical X Ceptor Therapeutics Inc
Application granted granted Critical
Publication of ATE496893T1 publication Critical patent/ATE496893T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03814127T 2002-12-20 2003-12-17 Isochinolinonderivate und deren verwendung als medikamente ATE496893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43585102P 2002-12-20 2002-12-20
PCT/US2003/040275 WO2004058717A1 (en) 2002-12-20 2003-12-17 Isoquinolinone derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE496893T1 true ATE496893T1 (de) 2011-02-15

Family

ID=32682285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814127T ATE496893T1 (de) 2002-12-20 2003-12-17 Isochinolinonderivate und deren verwendung als medikamente

Country Status (8)

Country Link
US (2) US7265131B2 (de)
EP (1) EP1572660B1 (de)
AT (1) ATE496893T1 (de)
AU (1) AU2003301020A1 (de)
DE (1) DE60335911D1 (de)
ES (1) ES2361924T3 (de)
TW (1) TW200418801A (de)
WO (1) WO2004058717A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1831225A2 (de) 2004-11-19 2007-09-12 The Regents of the University of California Entzündungshemmende pyrazolopyrimidine
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
KR20090086084A (ko) 2006-11-30 2009-08-10 코와 가부시키가이샤 치환 카르비놀 화합물
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CL2008001903A1 (es) * 2007-06-29 2009-03-06 Harvard College Linea celular que comprende una o mas celulas que expresan en forma estable una secuencia de acidos nucleicos que codifica un promotor regulador de esteroles y que esta unida en forma operativa a una secuencia de acidos nucleicos que codifica una etiqueta detectable; y metodo para determinar si un compuesto reduce el colesterol.
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
JP5371118B2 (ja) 2008-04-30 2013-12-18 興和株式会社 キノリン化合物
EP2285217A4 (de) * 2008-05-12 2011-06-08 Amnestix Inc Verbindungen zur verbesserung von lernfähigkeit und gedächtnis
AU2009252615B2 (en) 2008-05-29 2013-08-15 Kowa Company, Ltd. Substituted carbinol compound having cyclic linker
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2358720B1 (de) 2008-10-16 2016-03-02 The Regents of The University of California Heteroarylkinasehemmer mit kondensierten ringen
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
EP2408300B1 (de) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
KR101671046B1 (ko) 2009-04-29 2016-10-31 코와 가부시키가이샤 헤테로환 링커를 갖는 카르비놀 화합물
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
SG10201607345YA (en) 2012-03-02 2016-11-29 Ralexar Therapeutics Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102875466A (zh) * 2012-04-23 2013-01-16 中国药科大学 异喹啉酮衍生物,其制备方法及其医药用途
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ire1の調節
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
RS60479B1 (sr) 2013-09-04 2020-08-31 Ellora Therapeutics Inc Modulatori receptora x jetre (lxr)
JP2016532713A (ja) 2013-09-04 2016-10-20 アレクサー セラピューティクス, インク. 肝臓x受容体(lxr)調節因子
EP3044221B1 (de) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituierte isochinolin-1-on-verbindungen und deren therapeutische anwendung
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3402477A4 (de) 2016-01-11 2019-08-21 The Rockefeller University Verfahren zur behandlung von erkrankungen im zusammenhang mit aus myeloid abgeleiteten suppressorzellen
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN117486753B (zh) * 2023-10-13 2026-04-03 天津科技大学 一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物、方法及在驱蚊剂中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452027A (en) * 1967-07-03 1969-06-24 American Home Prod 2-hydroxyalkylisocarbostyrils
JPS5424882A (en) 1977-07-22 1979-02-24 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compounds and their preparation
US5115626A (en) * 1988-09-30 1992-05-26 Rapak, Inc. Apparatus for filling flexible plastic bags carried in a continuous web and supplies therefore
US4969310A (en) * 1989-05-12 1990-11-13 Automated Packaging Systems, Inc. Packaging machine and method
CA2028538A1 (en) 1989-10-27 1991-04-28 Hideaki Natsugari 4-substituted isoquinolone derivatives, their production and use
US5187917A (en) * 1990-10-29 1993-02-23 Cvp Systems, Inc. Automatic packaging apparatus and method and flexible pouch therefor
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
DE69224115T2 (de) 1991-07-30 1998-08-20 Ciba Geigy Ag Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren
US5260316A (en) 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5334600A (en) 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
JP3141051B2 (ja) 1992-10-09 2001-03-05 日清製粉株式会社 抗動脈硬化剤
SE501545C2 (sv) * 1993-05-05 1995-03-13 Jan Jostler Bana för förpackningsämnen samt sätt att öppna och fylla förpackningsfickor i banan
US5607898A (en) 1993-08-02 1997-03-04 Idemitsu Kosan Company, Ltd. Pyrazole derivatives
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
US5642599A (en) * 1994-11-14 1997-07-01 Tisma Machinery Corporation Automatic packaging machine for boxes with paper end liners
FR2728900B1 (fr) 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
US5747661A (en) 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
EP0828738B1 (de) 1995-05-26 2003-12-17 Bayer CropScience AG Pyridyl-thiazole und deren verwendung zum schutz von pflanzen gegen befall durch mikroorganismen
EP0845460A4 (de) 1996-05-15 1998-09-02 Toray Industries VERFAHREN ZUR HERSTELLUNG VON 4a-ARYLDECAHYDROISOCHINOLIN-DERIVATEN
US5939551A (en) 1996-05-15 1999-08-17 Toray Industries, Inc. Process for producing 4a-aryldecahydroisoquinoline derivatives
FR2750427B1 (fr) 1996-06-28 1998-08-07 Synthelabo Derives de 1-oxo-1, 2-dihydroisoquinoleine-4-propanamide, leur preparation et leur application en therapeutique
US5743070A (en) * 1996-08-16 1998-04-28 Automated Packaging Systems, Inc. Packaging machine, material and method
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
CN1248916A (zh) 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
EP0999208A4 (de) 1997-05-30 2001-08-08 Meiji Seika Kaisha Stickstoffhaltige heterozyklische verbindungen und heilmittel zu behandlung von hyperlipämie die diese enthalten
FR2772760B1 (fr) 1997-12-22 2000-02-04 Synthelabo Derives de 3-oxazol-5-yl-1-oxo-1,2-dihydroisoquinoleine-4- propanamide, leur preparation et leur application en therapeutique
EP1115853A2 (de) 1998-09-23 2001-07-18 Ludmila Solomin "in vivo" analyse von ligand-activierten kernrezeptoren i
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1165135B1 (de) 1999-03-26 2004-09-01 City of Hope Verfahren zur selektion von fxr-rezeptormodulatoren
CN1187364C (zh) 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
CA2382562A1 (en) 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
US6673543B2 (en) 2000-04-05 2004-01-06 Tularik, Inc. Solid phase synthesis of LXR ligands
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
ATE507210T1 (de) * 2002-03-07 2011-05-15 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren

Also Published As

Publication number Publication date
WO2004058717A8 (en) 2004-08-19
US7265131B2 (en) 2007-09-04
WO2004058717A1 (en) 2004-07-15
AU2003301020A1 (en) 2004-07-22
EP1572660A1 (de) 2005-09-14
ES2361924T3 (es) 2011-06-24
TW200418801A (en) 2004-10-01
US20040204447A1 (en) 2004-10-14
EP1572660B1 (de) 2011-01-26
US20080132521A1 (en) 2008-06-05
AU2003301020A8 (en) 2004-07-22
DE60335911D1 (de) 2011-03-10

Similar Documents

Publication Publication Date Title
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ATE547416T1 (de) Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
DE60221969D1 (de) Durch piperidine-enthaltende gruppen substituierte chinoline und deren stickstoff-enthaltende derivate und ihre verwendung als antibakterielle wirkstoffe
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
MY137535A (en) New pyrrolidinium derivatives
DE502004006507D1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
DE60118975D1 (de) Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE60124761D1 (de) Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel
ATE556056T1 (de) Pyridylderivate und deren verwendung als therapeutische mittel
DE69431069D1 (de) Cyclische amidderivate als neurokinin a antagonisten
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE495187T1 (de) Dalda-analoge und ihre verwendung
SE0104250D0 (sv) Heterocyclic compounds
ATE481103T1 (de) Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
DE602004031410D1 (de) Inden derivate als pharmazeutika
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE277010T1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties